419 related articles for article (PubMed ID: 33551196)
1. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
Coleman RL; Hu W; Soliman P; Nick A; Ramirez PT; Westin SN; Garcia ME; Zhu Z; Palancia J; Fellman BM; Yuan Y; Ram P; Bischoff F; Schmeler K; Bodurka D; Meyer LA; Sood AK
Gynecol Oncol; 2021 Apr; 161(1):104-112. PubMed ID: 33551196
[TBL] [Abstract][Full Text] [Related]
2. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Secord AA; Teoh DK; Barry WT; Yu M; Broadwater G; Havrilesky LJ; Lee PS; Berchuck A; Lancaster J; Wenham RM
Clin Cancer Res; 2012 Oct; 18(19):5489-98. PubMed ID: 22837181
[TBL] [Abstract][Full Text] [Related]
4. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
Secord AA; Havrilesky LJ; Carney ME; Soper JT; Clarke-Pearson DL; Rodriguez GC; Berchuck A
Int J Clin Oncol; 2007 Feb; 12(1):31-6. PubMed ID: 17380438
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
6. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial).
Ito K; Tsubamoto H; Itani Y; Kuroboshi H; Fujita H; Nobunaga T; Coleman RL
Gynecol Oncol; 2011 Feb; 120(2):193-7. PubMed ID: 21075434
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers S; Secord AA; Havrilesky L; O'Malley DM; Backes FJ; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi K; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
Clin Cancer Res; 2020 Aug; 26(15):3928-3935. PubMed ID: 32601075
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
Bevis KS; Kilgore LC; Alvarez RD; Straughn JM; Leath CA
J Reprod Med; 2014; 59(3-4):113-20. PubMed ID: 24724218
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Nomura H; Aoki D; Takahashi F; Katsumata N; Watanabe Y; Konishi I; Jobo T; Hatae M; Hiura M; Yaegashi N
Ann Oncol; 2011 Mar; 22(3):636-642. PubMed ID: 20696677
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.
Sovak MA; Dupont J; Hensley ML; Ishill N; Gerst S; Abu-Rustum N; Anderson S; Barakat R; Konner J; Poyner E; Sabbatini P; Spriggs DR; Aghajanian C
Int J Gynecol Cancer; 2007; 17(1):197-203. PubMed ID: 17291253
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
[TBL] [Abstract][Full Text] [Related]
14. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
[TBL] [Abstract][Full Text] [Related]
15. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
[TBL] [Abstract][Full Text] [Related]
16. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
17. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
Michener CM; Peterson G; Kulp B; Webster KD; Markman M
J Cancer Res Clin Oncol; 2005 Sep; 131(9):581-4. PubMed ID: 15959825
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin.
Kudlowitz D; Velastegui A; Musa F; Muggia F
Cancer Chemother Pharmacol; 2018 May; 81(5):847-851. PubMed ID: 29516152
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
Simpkins F; Drake R; Escobar PF; Nutter B; Rasool N; Rose PG
Gynecol Oncol; 2015 Feb; 136(2):240-5. PubMed ID: 25485782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
